Myeloperoxidase impairs the contractile function in isolated human cardiomyocytes

Judit Kalász1, Enikő T Pásztor1, Miklós Fagyas1

  • 1Division of Clinical Physiology, Institute of Cardiology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.

Insights

Myeloperoxidase (MPO) activation impairs cardiomyocyte function by altering active and passive forces and calcium sensitivity. These detrimental effects, independent of protein oxidation, can be prevented by MPO inhibition, suggesting a therapeutic target for inflammation-induced heart dysfunction.

Area of Science:

  • Cardiovascular Biology
  • Biochemistry
  • Cell Physiology

Background:

  • Myeloperoxidase (MPO) is an enzyme implicated in inflammatory responses.
  • Oxidative stress and protein modifications are key factors in cardiovascular dysfunction.

Purpose of the Study:

  • To investigate the mechanical effects of MPO on human cardiomyocytes.
  • To identify MPO-induced myofilament protein modifications and their functional consequences.
  • To evaluate the therapeutic potential of MPO inhibition.

Main Methods:

  • Isolated left-ventricular human cardiomyocytes were studied.
  • Mechanical properties (active and passive force, Ca2+ sensitivity) were measured.
  • MPO activity, protein carbonylation, and sulfhydryl group oxidation were assessed.

Main Results:

  • MPO activation significantly reduced active force and Ca2+ sensitivity while increasing passive force.
  • MPO-induced functional changes were independent of direct SH-group oxidation and carbonylation of actin, myosin-binding protein C, and titin.
  • MPO inhibition and the antioxidant Met prevented MPO-induced cardiomyocyte dysfunction.

Conclusions:

  • MPO activation directly impairs cardiomyocyte mechanical function and Ca2+ regulation.
  • Targeting MPO may offer a novel therapeutic strategy to mitigate myocardial contractile dysfunction during inflammatory conditions.